TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41054

Peptide_Name

Sample Peptide 2 from US011339203B2

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 35-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR-NH2

FASTA

>TPDB41054|Anticancer|length=35
FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR-NH2

Formula C178H309N55O47

Absent Amino Acids CEQHMPW

Common Amino Acids L

Mass 3971.75

PI 11.53

Basic Residues 9

Acidic Residues 2

Hydrophobic Residues 16

Net Charge +7

Boman Index 4.87

Hydrophobicity -0.291

Aliphatic Index 120.00

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 1490

Absorbance 280nm 37.51

Polar Residues 7

number

4

A

4

R

3

N

2

D

0

C

0

E

0

Q

2

G

0

H

1

I

8

L

5

K

0

M

1

F

0

P

1

S

2

T

0

W

1

Y

1

V

Amino Acid Distribution

A: 4 R: 4 N: 3 D: 2 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 1 L: 8 K: 5 M: 0 F: 1 P: 0 S: 1 T: 2 W: 0 Y: 1 V: 1

Length

35

Formula

C178H309N55O47

Mass

3971.75

PI

11.53

Net Charge

+7

Boman Index

4.87

Hydrophobicity

-0.291

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

Synthetic

Evidence 1 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 0.4% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Renal Cancer

Cell Line CAKI-2

Tissue Affected Kidney

Assay & Model

Assay CCK-8 assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Patents US011339203B2

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 2.5% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Kidney

Assay & Model

Assay CCK-8 assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Patents US011339203B2

Evidence 3 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 0.2% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Skin Cancer

Cell Line A-2058

Tissue Affected Skin

Assay & Model

Assay CCK-8 assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Patents US011339203B2

Evidence 4 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 0.6% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Lung Cancer

Cell Line NCI-H2444

Tissue Affected Lung

Assay & Model

Assay CCK-8 assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Patents US011339203B2

Evidence 5 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 1.4% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay CCK-8 assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Patents US011339203B2